...
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms
【24h】

Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms

机译:一项双中心,双盲,随机对照试验的患者报告的乳腺癌女性结局,评估了针灸对减轻芳香化酶抑制剂引起的肌肉骨骼症状的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. Methods Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. Results The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P =.022), hot flash severity (P =.006), hot flash frequency (P =.011), the HFRDI (P =.014), and NSABP menopausal symptoms (P =.022); scores in the SA arm improved significantly on the EuroQol (P =.022),the HFRDI (P =.043), and NSABP menopausal symptoms (P =.005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P <.001) and frequency (P <.001) scores. Conclusions Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study.
机译:背景芳香酶抑制剂(AIs)与患者报告的结局(PROs)减少有关。这项研究的目的是评估与假针刺(SA)相比,真实针刺(RA)是否可以改善正在接受辅助AI的乳腺癌患者的PRO。方法在一项双中心,随机对照试验中,将接受AI且具有治疗相关性肌肉骨骼症状的绝经后0至III期乳腺癌妇女随机分为8周,每周一次RA与SA对比。美国国家外科手术辅助乳房和肠项目(NSABP)的更年期症状调查表,抑郁症流行病学研究中心量表(CESD),医院焦虑和抑郁量表(HADS),匹兹堡睡眠质量指数(PSQI),每日热潮日记,与潮热相关的每日干扰量表(HFRDI)和欧洲生活质量调查(EuroQol)用于评估基线和4周,8周和12周的PRO。结果意向性治疗分析包括RA组23例和SA组24例。两组之间的基线特征无显着差异。与基线相比,在第8周时,RA评分在CESD(P = .022),潮热严重程度(P = .006),潮热频率(P = .011),HFRDI(P =。 014)和NSABP更年期症状(P = .022); EuroQol(P = .022),HFRDI(P = .043)和NSABP更年期症状(P = .005)显着改善了SA组的评分。事后分析表明,与非非裔美国患者(n = 38)相比,非裔美国人(n = 9)从RA中受益比SA多于SA,从而降低了潮热严重程度(P <.001)和频率(P <.001)。 )得分。结论RA和SA均与接受AI的乳腺癌患者的PROs改善有关,两组之间无显着差异。针灸反应的种族差异值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号